Introduction: Gerstmann-Sträussler-Scheinker disease P105L (GSS105) is a rare vari-
| INTRODUC TI ON
Gerstmann-Sträussler-Scheinker disease (GSS) is an autosomal dominant neurodegenerative disorder caused by prion protein (PrP) gene (PRNP) mutations on chromosome 20 (Ghetti, Tagliavini, Kovacs, & Piccardo, 2011) . GSS is clinically characterized by a constellation of signs and symptoms, and the cardinal neuropathological feature of GSS is the formation of amyloid plaques composed of PrP (PrP-plaques) that are most abundant in the cerebral cortex, basal ganglia, and cerebellar cortex (Ghetti et al., 2011) . GSS P105L (GSS105), a rare variant of GSS caused by a point mutation of PRNP at codon 105 (proline to leucine substitution), was first reported in Japan (Kitamoto, Amano, et al., 1993; Yamada et al., 1993) and is clinically characterized by gait disturbance (spastic paraparesis), dementia, or psychiatric disorders (Amano et al., 1992; Isshiki, Minagawa, & Yamauchi, 1994; Itoh et al., 1994; Kitamoto, Amano, et al., 1993; Kubo, Nishimura, Shikata, Kokubun, & Takasu, 1995; Nakazato, Ohno, Negishi, Hamaguchi, & Arai, 1991; Yamada et al., 1993 ).
More than 20 years ago, two members of a Japanese GSS105 family were reported as separate case reports in Japanese (Isshiki et al., 1994; Nakazato et al., 1991) . Both of these cases presented with spastic paraparesis and later with dementia and so on, and were subjected to autopsy. Neuropathological examination disclosed numerous PrP-plaques in the cerebrum and cerebellum, and pyramidal tract degeneration was noted in the brain stem and spinal cord (Isshiki et al., 1994; Nakazato et al., 1991) . Recently, we had the opportunity to learn of the third patient from this GSS105 family. This case was also subjected to autopsy limited to the brain, and a detailed neuropathological assessment was possible.
The paraffin blocks of the previous two cases had been stored in whole in our institution (Saitama Medical University). Given such a situation, we decided to undertake a comprehensive study that aims to compare the clinicopathological profiles among the three cases.
GSS is known to be associated with hyperphosphorylated tau (phospho-tau: p-tau) deposition (Alzualde et al., 2010; Colucci et al., 2006; Ghetti et al., 1995 Ghetti et al., , 1996 Ghetti et al., , 1994 Hsiao et al., 1992; Ichimiya et al., 1994; Ikeda, Yanagisawa, Glenner, & Allsop, 1992; Ishizawa et al., 2002; Kitamoto, Lizuka, et al., 1993; Piccardo et al., 1998; Tranchant et al., 1997) . Typically, p-tau lesions are present in the form of neurofibrillary tangles (NFTs), dystrophic neurites (DNs), and/or neuropil threads (NTs) in or around PrPplaques. In a previous report of a GSS P102L (GSS102) patient complicated with dementia (Ishizawa et al., 2002) , a full-blown pathology comprised of PrP, p-tau, and beta-amyloid (Aβ) was present, and an interesting interaction of PrP, p-tau, and Aβ was suggested. In a preliminary study of the present GSS105 cases, a considerable amount of p-tau was found. A comprehensive analysis using single-and multiple-labeling immunohistochemistry, which aims to further clarify the topological relationship among the three proteins, PrP, p-tau, and Aβ, is another theme of this study.
| MATERIAL S AND ME THODS

| Case materials and clinical history
The family tree of the three kindred is shown in Figure 1 . Case 1 and Case 2 are sisters, and Case 3 is the son of Case 2. The parents of Case 1 and Case 2 are a married couple between cousins. Although the details are unknown, there is another sibling of Case 1 and Case 2, who was affected with spastic paraparesis, dementia, and cerebellar dysfunction (Figure 1 ). The clinicopathological and genetic profiles of Case 1 (Isshiki et al., 1994; Kitamoto, Amano, et al., 1993; Nakazato et al., 1991) and Case 2 (Isshiki et al., 1994; Kitamoto, Amano, et al., 1993) were previously reported in Japanese (Isshiki et al., 1994; Nakazato et al., 1991) and English (Kitamoto, Amano, et al., 1993 (Kitamoto, Amano, et al., 1993) correspond to Case 1 and Case 2 in this report, respectively). Case 3 is the virgin case that remains to be reported.
| Case 1
Since the clinical history of this patient, a 45-year-old woman at death, is already available elsewhere in Japanese (Nakazato et al., 1991) , this report only describes the outline of it. At the age of 38, she manifested with difficulty in walking. A neurological examination 6 months after the onset disclosed spastic gait coupled with spasticity and pyramidal signs in both legs. A clinical diagnosis of "familial spastic paraparesis" was made. Two years after the onset, she became unable to walk. Soon dysarthria, emotional incontinence, and tremor of the tongue and fingers appeared. Eventually, she became severely demented and died of aspiration pneumonia 6 years after the onset.
| Case 2
Since the clinical history of this patient, a 56-year-old woman at death is already available elsewhere in Japanese (Isshiki et al., 1994) ,
autopsy, beta-amyloid, Gerstmann-Sträussler-Scheinker disease P105L, prion protein, spastic paraparesis, tau this report only describes the outline of it. When she was 5 years old, she was affected with poliomyelitis. Since then her right hand remained paralytic, but there was no problem in her daily life. At the age of 44, she manifested with difficulty in walking, and 4 months later, she became almost unable to walk. Soon dysarthria became evident. About 2 years after the onset, a clinical diagnosis of "familial spastic paraparesis" was made, and thereafter, she became bedridden. Then, she was admitted to a psychiatric hospital for the management of severe emotional disturbance. The pyramidal signs in the upper and lower limbs, chorea-like movement in the left upper limb, apathy, and dementia followed, and she died at the age of 56, 12 years after the onset.
| Case 3
This patient, a 49-year-old man at death, is the son of Case 2. When he was 47 years old, he suffered from hemorrhoids and had them surgically removed. But after the operation, he repeatedly complained of anal pain and kept on consulting several hospitals. Soon, the family members found his way of walking somewhat clumsy.
About 1 year later, he presented with tremor in his fingers. About 2 years after the onset, his stereotyped behavior and speech became more apparent; he walked around the same place at the same time each day; and he dropped in at the same store and bought the same foods (bread and cola). There was an episode where he complained of lucency of his teeth, and he consulted a dentist three days in a row. He began to make comments like "I have been deceived," or "I have been robbed." He became restless and easily agitated, which culminated in an attempted strangulation of his wife. He was hospitalized and remained conscious but did not utter any words. There was a tremor in the upper limbs, and there was myoclonus, which disappeared later, in the lower limbs. In all extremities, deep tendon reflexes were exaggerated but there was no paresis. There were no signs of sensory and cerebellar impairment. During the hospitalization, he relentlessly complained of anal pain and repeatedly ate the same foods (hamburgers and cola). The brain magnetic resonance imaging (MRI) showed mild frontotemporal atrophy, but did not disclose any signal abnormalities on diffusion MRI. The complaint of anal pain was so tenacious that oral morphine was introduced. But he unexpectedly passed away due to paralytic intestinal obstruction leading to septic shock. The whole clinical course was about 2 years (2 years and 3 months). The P105L point mutation of PRNP coupled with codon 129 polymorphism (Val/Met), which is identical to that of Case 1 and Case 2 (Kitamoto, Amano, et al., 1993) , was detected by a genetic analysis using blood samples. An autopsy limited to the brain was performed. Table 1 summarizes representative symptoms and some laboratory data of the three cases with the help of previous papers (Isshiki et al., 1994; Kitamoto, Amano, et al., 1993; Nakazato et al., 1991) and medical records available in our institution.
| Tabulation of the clinical profiles compared among the three cases
| Preparation of paraffin blocks and histological evaluation
The paraffin blocks of Case 1 and Case 2, which had been stored in Saitama Medical University, were retrieved for re-evaluation of histology and immunohistochemistry; however, as PrP in these blocks had not been detoxicated before, the detoxication step by formic
The family tree of the three cases is shown. Other than the three cases analyzed in this study (arrows), there is another sibling (*), a 55-year-old woman at death, who showed spastic paraparesis, dementia, and cerebellar dysfunction. Square, male; circle, female; diamond, an individual whose information of sex is unavailable; +, dead. Closed symbols indicate an individual with definite or possible GSS105-associated symptoms acid treatment was necessary. The paraffin blocks were immersed several times in xylene for deparaffinization then were immersed in ethanol, and finally in tap water. The deparaffinized blocks were immersed in 100% formic acid for 1 hr. After this disinfection step, the blocks were paraffinized again. With respect to Case 3, the brain was fixed in 10% buffered formalin, and representative sections were sliced. The sections were immersed in concentrated formic acid (98%) for 1 hr, washed in tap water, and embedded in paraffin.
The histology was evaluated using hematoxylin and eosin (HE), Klüver-Barrera (KB), HE-Luxol fast blue (LFB), and/or Bodian stains.
Gallyas silver stain was applied to all cases to evaluate neurofibrillary pathology.
| Single-and multiple-labeling immunohistochemistry for PrP, p-tau, and Aβ
Primary antibodies used for single-labeling immunohistochemistry were as follows: mouse monoclonal antibodies for PrP (3F4; 1:1,000 or 1:2,000; Dako, Carpinteria, CA, USA, (Kascsak et al., 1987) ), ptau (AT8; 1:1,000; Innogenetics, Ghent, Belgium; Goedert, Jakes, & Vanmechelen, 1995; Mercken et al., 1992) , three repeat tau (RD3; 1:1,000; Upstate Biotechnology, Lake Placid, NY, USA; de Silva et al., 2003) , four repeat tau (RD4; 1:100; Upstate Biotechnology; de Silva et al., 2003) , and Aβ (4G8; 1:20,000; Senetek, St. Louis, MO, USA; Kim et al., 1990) . Antigen retrieval pretreatment was as follows: hydrolytic autoclaving in 1 mM HCl (121℃, 10 min) for 3F4, hydrolytic autoclaving in 10 mM EDTA (121℃, 10 min) for RD3 and RD4, and immersion in concentrated formic acid (98%, room temperature, 5 min) followed by washing in phosphate buffered saline (PBS) for 4G8. Single-labeling immunohistochemistry was carried out as follows: the deparaffinized and rehydrated 5 μm-thick sections were treated with the antigen retrieval pretreatment according to the primary antibody, washed in PBS, and incubated with the primary antibody (37℃, 60 min). Then, the sections were washed in PBS and treated with 3% hydrogen peroxide (room temperature, 10 min).
After washing in PBS, the sections were incubated with a secondary antibody kit (Dako ChemMate EnVision kit/HRP (DAB)) (room temperature, 30 min). After washing in PBS, the sections were visualized with diaminobenzidine (DAB). and PrP-N, and/or a rabbit polyclonal anti-tau antibody (1:1,000, A 024, Dako) and 4G8. PrP-N is an excellent antibody, as is 3F4, which can be used to visualize PrP-plaques . The use of PrP-N and 3F4 in immunohistochemistry is exchangeable, and both antibodies were successfully applied to single-and multiplelabeling immunohistochemistry in a previous study of GSS (Ishizawa 
| Comparative semi-quantitative analyses of tissue injuries and 3F4-immunoreactive PrP-plaques among the three cases
To compare the three cases, the neuroanatomic structures, including the cerebral cortices and white matter, basal ganglia (putamen, globus pallidus, and/or caudate nucleus), thalamus, hippocampus, brain stem, cerebellar cortices and white matter, and spinal cord, were semi-quantified on HE, KB, and HE-LFB sections for tissue injuries (neuronal loss, gliosis, spongiform change, and/or myelin loss/pallor) in the most affected portion as ± (none or few: minimal), + (mild), ++ (moderate), and +++ (severe). As for PrP-plaques visualized by 3F4-immunohistochemistry, they were semi-quantified in the portion showing the highest density of immunoproducts as -(none), + (sparse), ++ (moderate), and +++ (frequent) with a reference to the semi-quantification strategy for senile plaques in Alzheimer's disease (AD) (CERAD) (Fillenbaum et al., 2008; Mirra et al., 1991) . In the cerebral cortices, as the PrP-plaques were distributed in a layer-dependent manner, the semi-quantification was subdivided into the superficial (layers I and II), middle (III and IV), and deep (V and VI) cortical layers. 
| Case 2
The brain, whose weight was 975 g, was considerably atrophic, par- 
| Case 3
The brain, which weighed 1,560 g, was mildly atrophic in the frontal and temporal lobes ( Figure 2I and II). In the cerebral cortices, neuronal loss and gliosis as well as spongiform change were only minimal ( Figure 2III ). PrP-plaques were identified, particularly along the deep cortical layers ( Figure 2III-V) . In the basal ganglia, hippocampus, and thalamus, a variable number of PrP-plaques were visualized by PrP-immunohistochemistry ( Figure 2VI ,VII). The 
(HE). (IV) A PrP-plaque in the temporal cortex (arrow, HE). (V) PrP-plaques in the frontal cortex, particularly along the deep cortical layers (3F4-immunostain). (VI) PrP-plaques in the putamen (3F4-immunostain). (VII) PrP-plaques in the thalamus (3F4-immunostain). (VIII) In the cerebellum, PrP-plaques are absent (3F4-immunostain). (IX) The cerebral white matter shows mild myelin loss/pallor (KB). (X)
In the medullary pyramid, myelin is well-preserved (KB) cerebellum was unremarkable with no deposition of PrP-plaques ( Figure 2VIII ). The cerebral white matter showed mild myelin loss/ pallor ( Figure 2IX ). The brain stem, including the pyramidal tract, was unremarkable ( Figure 2X ).
| Comparative semi-quantitative analyses of tissue injuries and PrP-plaques visualized by 3F4-immunohistochemistry
The tissue injuries and PrP-plaques visualized by 3F4-immunohistochemistry, which were semi-quantified for the three cases, are presented in Tables 2 and 3 , respectively. The tissue injuries were the most prominent in Case 2, which was followed by Case 1 and then by Case 3.
The pyramidal tract in Case 1 and Case 2 was severely affected, while that in Case 3 remained intact. Similarly, the PrP-plaques visualized by 3F4-immunohistochemistry were the most numerous in Case 2, which was followed by Case 1 and then by Case 3. Particularly in Case 2, a large number of PrP-plaques were noted not only in the cerebrum but also in the cerebellum. Even in Case 3, who was the youngest and had the shortest clinical course, there were a fair number of PrP-plaques in the cerebrum, especially along the deep cortical layers.
| Single-and multiple-labeling immunohistochemistry for PrP, p-tau, and Aβ
The frontal lobe, temporal lobe, parietal lobe (except for Case 2), occipital lobe, hippocampus, and/or cerebellum were analyzed for the topological relationship of PrP, p-tau, and Aβ (Figures 3-5 ).
In Case 1 (Figure 3 ), PrP-plaques and p-tau were scattered in the cerebral cortices (Figure 3a Similarly to Case 1, p-tau was by far the most numerous in the temporal lobe and hippocampus, but was absent in the cerebellum. In this case, the deposition of Aβ was also noted in the cerebral cortices (Figure 4c ), but not in the hippocampus (Figure 4f ) and cerebellum.
Notably, the majority of Aβ had an immuno-negative central core (Figure 4c ), which later turned out to be PrP (Figure 4j ). Similarly to 
| Single-labeling immunohistochemistry for three repeat tau (RD3) and four repeat tau (RD4)
In all cases, both three repeat tau (RD3) and four repeat tau (RD4) were associated with PrP-plaques (Case 1, Figure 6a 
| D ISCUSS I ON
Clinically, Case 1 and Case 2, who were female siblings, manifested with spastic paraparesis, which was then followed by dysarthria, psychiatric symptoms, and dementia. Case 3, who was the son of Case 2, manifested with psychiatric symptoms, such as stereotyped speech and behavior; but in contrast to Case 1 and Case 2, there were no signs of spastic paraparesis during the whole clinical course.
Although the clinical picture of GSS105 is usually predominated by gait disturbance (spastic paraparesis), psychiatric symptoms, and dementia (Amano et al., 1992; Isshiki et al., 1994; Itoh et al., 1994; Kitamoto, Amano, et al., 1993; Kubo et al., 1995; Nakazato et al., 1991; Yamada et al., 1993) , there is a substantial variation to it even within the same family (Iwasaki, Kizawa, Hori, Kitamoto, & Sobue, 2009; Koshi Mano et al., 2016; Shiraishi, Mizusawa, & Yamada, 2002; Yamada et al., 1999 Yamada et al., , 1995 Yamazaki et al., 1999) . In a GSS105 family reported elsewhere (Shiraishi et al., 2002; Yamazaki et al., 1999) , one member presented with gait disturbance (gait apraxia) that was followed by mutism (Yamazaki et al., 1999) , and the other presented with sensory and psychiatric symptoms, including a persistent complaint of pains in various parts of the body, which were then followed by memory disturbance, delusion, and gait disturbance (Shiraishi et al., 2002) . A recent paper described three GSS105 families (Families Note. yo, years old; M, male; F, female; NA, not available; ±, none or few (minimal); +, mild; ++, moderate; +++, severe.
TA B L E 3
Comparative semi-quantitative analysis of PrP-plaques visualized by 3F4-immunohistochemistry among the three cases 1, three of the four affected individuals manifested with gait disturbance, and the remaining one manifested with dysesthesia and gait disturbance. Not only parkinsonism but also other neurological signs, such as spasticity, ataxia, involuntary movement, dementia, or emotional instability, were variably noted in all families. Taken together with these reports and others (Amano et al., 1992; Iwasaki et al., 2009; Kubo et al., 1995; Yamada et al., 1999 Yamada et al., , 1995 , the present study asserts a wide spectrum of symptoms associated with GSS105 even within the same family. The same is true for other mutations of GSS (Giovagnoli et al., 2008; Hsiao et al., 1991; Kovacs et al., 2001; Majtenyi, Brown, Cervenakova, Goldfarb, & Tateishi, 2000; Mastrianni et al., 1995; Nochlin et al., 1989; Piccardo et al., 1998; Popova et al., 2012; Webb et al., 2008) . In this respect, though one point merits mention about the clinical profile of the present Case 3:
this patient died of paralytic intestinal obstruction leading to septic shock about 2 years after the onset. Based on his clinical history, this comorbidity is more than likely the result, not of GSS105 itself, but of the oral administration of morphine. In fact, intestinal symptoms have rarely been reported in GSS105 (Iwasaki et al., 2009; Koshi Mano et al., 2016) . The death of the patient is rather unexpected, and his clinical course, about 2 years in all, is much shorter than those expected for GSS105 (Iwasaki et al., 2009 ). This could have contributed to the lack of some clinical features compared to the other two cases. For example, although spastic paraparesis was not evident in this patient, 
it was recorded that his way of walking was clumsy and deep tendon reflexes were exaggerated. These neurological signs could have been a prelude to spastic paraparesis that could have been possible later if the patient had not prematurely passed away.
Pathologically, in Case 1 and Case 2, the cerebral cortices and pyramidal tract were severely affected. In contrast, in Case 3, the cerebral cortices were relatively preserved, and the pyramidal tract remained uninvolved.
The clinicopathological study of GSS105 with a focus of comparison between individuals within the same family is so far available in two families; one is no other than the present family, the two members of which were previously reported (Isshiki et al., 1994; Kitamoto, Amano, et al., 1993; Nakazato et al., 1991) , and the other is the one reported by (Yamada et al. 1999; Itoh et al., 1994) . The latter family is comprised of two siblings affected by the disease. One was a male patient whose initial symptom was clumsiness of the right hand at the age of 42, which was followed by spastic paraparesis. Subsequently, he showed signs of ataxia of the extremities, memory impairment, dysarthria, and apraxia.
He died at the age of 53. At autopsy, the brain weighed 1,150 g and showed frontal atrophy. In the cerebral cortices, various sizes of compact and amorphous PrP-plaques were noted, and the pyramidal tract was degenerated from the brain stem to the spinal cord. The other was the sister of the first patient, who initially presented with difficulty in writing because of tremulous movements of the upper extremities, which was followed by gait disturbance, involuntary movement of the legs, speech disturbance, and character changes. When she was 56 years old, she showed emotional and intellectual disturbance. Her speech was scanning with a small voice, and action myoclonus was prominent in the extremities.
There was hyperreflexia of the legs. She died at the age of 58.
At autopsy, the brain weighed 1,200 g. The histopathology of this patient was similar to that of her brother; in the cerebral cortices, various sizes of compact and amorphous PrP-plaques were noted, and the pyramidal tract was degenerated from the brain stem to the spinal cord. Taken together with these reports, the present study indicates that the histopathology of GSS105 can considerably differ from individual to individual within the same family;
and yet, it is a good reflection of the symptoms of each patient.
Albeit with a few exceptions showing discordant clinicopathological correlations (Webb et al., 2008) , the same is true for other mutations of GSS (Colucci et al., 2006; Ghetti et al., 1989; Majtenyi et al., 2000; Nochlin et al., 1989; Popova et al., 2012) . In this respect, though, similarly to the first paragraph of this discussion, one point merits mention about the histological aspects of the present , 1996 Hsiao et al., 1992; Ichimiya et al., 1994; Ikeda et al., 1992; Kitamoto, Lizuka, et al., 1993) . Although less common, GSS102, 105, 117 (A117V), 187 (H187R), 202 (D202N), and 218 (Y218N) are also relevant examples (Alzualde et al., 2010; Colucci et al., 2006; Ghetti et al., 1995; Ishizawa et al., 2002; Piccardo et al., 1998; Tranchant et al., 1997) .
Previously, a full-blown pathology comprised of PrP, p-tau, and
Aβ was reported in a GSS102 patient, a 44-year-old man with a 7-year history of dementia (Ishizawa et al., 2002) . Numerous p-tau lesions, including NFTs, DNs, and NTs, were found in or around PrP-plaques. An interesting feature of this case was that although a considerable amount of Aβ was found, the majority of it was not colocalized with PrP-plaques. A computer-assisted image analysis targeting the cerebral cortices disclosed a positive and significant correlation between PrP and p-tau, but not between PrP and Aβ. A similar observation, where PrP was associated with p-tau, but not with Aβ, was also reported in a fraction of GSS patients (Amano et al., 1992; Colucci et al., 2006; Ichimiya et al., 1994; Itoh et al., 1994; Kitamoto, Lizuka, et al., 1993; Yamada et al., 1999) . In an in vitro experiment, the molecular interaction between tau and PrP was shown; the N-terminus and repeat region of tau are actively involved in its interaction with PrP, and more specifically, the GSS-related mutant of PrP, PrP102, was shown to have a higher tau-binding activity than wild-type PrP (Wang et al., 2008) . It is plausible that PrP in GSS possesses an intrinsic ability to induce p-tau deposition without the help of Aβ (Ishizawa et al., 2002; Reiniger et al., 2011) . Concerning biochemical properties of tau in GSS, the paired helical filaments, which are morphologically identical to those of AD, are reported in GSS145, 198, and 217 (Ghetti et al., 1995 , 1996 . Antigenic profiles of NFTs in GSS145 and 198 are shown to be similar, if not identical, to those in AD by immnocytochemistry and immunoblot analysis (Ghetti et al., 1995 (Ghetti et al., , 1996 (Ghetti et al., , 1994 Giaccone et al., 1990; Tagliavini et al., 1993) . In fact, the present study showed that p-tau lesions associated with PrPplaques contained both three repeat tau and four repeat tau, just as in AD (Siddiqua & Margittai, 2010) . Supposing PrP deposition were the primary pathology of GSS, p-tau deposition in GSS could be regarded as a "secondary degeneration" due to PrP deposition, just as p-tau deposition is likely a "secondary degeneration" due to Aβ deposition in AD (Hardy, Duff, Hardy, Perez-Tur, & Hutton, 1998) .
In this context, the finding of Case 2 merits particular attention. In this patient, a 56-year-old woman with a 12-year history of the disease, the majority of Aβ was colocalized with PrP-plaques, which was in sharp contrast to the GSS102 patient discussed above (Ishizawa et al., 2002) . Aβ deposition associated with PrP-plaques is also a known phenomenon in GSS (Ghetti et al., 1995 (Ghetti et al., , 1994 Ikeda et al., 1992; Miyazono, Kitamoto, Iwaki, & Tateishi, 1992; Tranchant et al., 1997); in GSS105, 117, 187, 198, 217, and 218 , the patients can show colocalization of PrP and Aβ within the same plaques (Alzualde et al., 2010; Amano et al., 1992; Colucci et al., 2006; Ghetti et al., 1995 Ghetti et al., , 1994 Ikeda et al., 1992; Itoh et al., 1994; Nochlin et al., 1989; Tranchant et al., 1997; Yamada et al., 1999; Yamazaki et al., 1999) . There are experimental models showing that PrP can bind Aβ with high affinity (Lauren, Gimbel, Nygaard, Gilbert, & Strittmatter, 2009; Li, 2016) . This phenomenon, however, seems dependent on the type of mutation of PRNP; in GSS145, PrP deposits are reported to be negative for Aβ (Ghetti et al., 1996; Ichimiya et al., 1994; Kitamoto, Lizuka, et al., 1993) . Furthermore, it should be borne in mind that the deposition of Aβ depends, to a certain extent, on the individual and old age Colucci et al., 2006; Miyazono et al., 1992; Ohgami, Kitamoto, Weidmann, Beyreuther, & Tateishi, 1991) , since not all members of GSS117, 198 or 217 family show Aβ deposition Colucci et al., 2006; Ghetti et al., 1995; Tranchant et al., 1997) . In accordance with a previous report showing a high concurrence of prion disease pathology and AD pathology in Creutzfeldt-Jacob-disease (Tousseyn et al., 2015) , the histopathology of the present Case 2 possesses strong evidence that Aβ deposition, as well as p-tau deposition, could be directly or indirectly induced by PrP itself ("secondary degeneration"). Probably Aβ deposition within PrP-plaques could facilitate p-tau deposition further. This kind of patho-mechanism should underlie the kaleidoscopic symptoms of GSS, which are always evolving and overlying one another.
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